Goldman Sachs resumes coverage on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) with a Buy. PT $52.00.

"ENDP is in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE